Towards medication-enhancement of cognitive interventions in schizophrenia

Abstract

Current antipsychotic medications do little to improve real-life function in most schizophrenia patients. A dispassionate view of the dispersed and variable neuropathology of schizophrenia strongly suggests that it is not currently, and may never be, correctable with drugs. In contrast, several forms of cognitive therapy have been demonstrated to have modest but lasting positive effects on cognition, symptoms, and functional outcomes in schizophrenia patients. To date, attempts to improve clinical outcomes in schizophrenia by adding pro-cognitive drugs to antipsychotic regimens have had limited success, but we propose that a more promising strategy would be to pair drugs that enhance specific neurocognitive functions with cognitive therapies that challenge and reinforce those functions. By using medications that engage spared neural resources in the service of cognitive interventions, it might be possible to significantly enhance the efficacy of cognitive therapies. We review and suggest several laboratory measures that might detect potential pro-neurocognitive effects of drugs in individual patients, using a test dose design, aided by specific biomarkers predicting an individual's drug sensitivity. Lastly, we argue that drug classes viewed as counter-intuitive based on existing models for the pathophysiology of schizophreniaincluding pro-catecholaminergic and NMDA-antagonistic drugsmight be important candidate pro-cognitive therapy drugs. © 2012 Springer-Verlag Berlin Heidelberg.